News headlines about AcelRx Pharmaceuticals (NASDAQ:ACRX) have trended somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. AcelRx Pharmaceuticals earned a news sentiment score of 0.08 on Accern’s scale. Accern also assigned media stories about the specialty pharmaceutical company an impact score of 46.0812945373029 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Shares of AcelRx Pharmaceuticals (ACRX) opened at $2.15 on Friday. The company has a market capitalization of $108.23, a P/E ratio of -1.92 and a beta of 2.96. The company has a debt-to-equity ratio of -0.43, a current ratio of 4.78 and a quick ratio of 4.71. AcelRx Pharmaceuticals has a 12 month low of $1.55 and a 12 month high of $5.75.
ACRX has been the subject of several analyst reports. ValuEngine upgraded AcelRx Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Tuesday, September 26th. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of AcelRx Pharmaceuticals in a research report on Tuesday, October 3rd. Roth Capital set a $8.00 target price on AcelRx Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, October 12th. Jefferies Group lowered AcelRx Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, October 13th. Finally, Royal Bank of Canada decreased their target price on AcelRx Pharmaceuticals from $6.00 to $5.00 and set an “outperform” rating for the company in a research report on Friday, October 13th. One research analyst has rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the company’s stock. AcelRx Pharmaceuticals presently has an average rating of “Hold” and an average target price of $6.18.
In other news, Director Mark G. Edwards bought 30,000 shares of the business’s stock in a transaction on Tuesday, November 14th. The shares were purchased at an average price of $1.90 per share, for a total transaction of $57,000.00. Following the purchase, the director now owns 150,000 shares of the company’s stock, valued at approximately $285,000. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 28.10% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This article was posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this article on another domain, it was stolen and republished in violation of U.S. & international copyright and trademark laws. The original version of this article can be accessed at https://www.thelincolnianonline.com/2018/01/14/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-acelrx-pharmaceuticals-acrx-share-price.html.
AcelRx Pharmaceuticals Company Profile
AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.
Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.